Status:
UNKNOWN
Phenotypic Profile and Molecular Mechanism of Resistance in Carbapenemase-producing Enterobacterales and Pseudomonas Aeruginosa Isolates From Brazilian Hospitals: Implications for the Introduction of IMIPENEM-RELEBACTAM
Lead Sponsor:
D'Or Institute for Research and Education
Conditions:
Bacterial Infections
Antibiotic Resistant Infection
Eligibility:
All Genders
18+ years
Brief Summary
The global dissemination of carbapenem-resistant Enterobacteriaceae (CRE) and Pseudomonas aeruginosa (CRPA) are a significant threat to health care, especially for severely ill patients. Antibiotics c...
Detailed Description
Prospective evaluation of 150 (one hundred and fifty) Enterobacterales and 100 (one hundred) Pseudomonas aeruginosa isolates from 12 hospitals in the city of Rio de Janeiro. A sequential number of iso...
Eligibility Criteria
Inclusion
- Microbiologics analysis indicating carbapenem resistance
Exclusion
- Microbiologics analysis indicating Negative class A and D cabapenemase gene
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2023
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT05285046
Start Date
April 1 2022
End Date
February 28 2023
Last Update
March 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
D'Or Institute for Research and Education (IDOR)
Rio de Janeiro, Brazil, 22281-100